Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR2 | P25090 | 5/20 | 0.54 |
| ▸ | HCRTR2 | O43614 | 11/20 | 0.47 |
| ▸ | HCRTR1 | O43613 | 5/20 | 0.40 |
| ▸ | FYN | P06241 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.38 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.38 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1167277 | 0.89 | FPR2 (0.56) | FPR2HCRTR2HCRTR1MEN1KMT2A | |
| SCHEMBL1166790 | 0.88 | FPR2 (0.68) | FPR2HCRTR2HCRTR1TSHRMEN1 | |
| SCHEMBL2331053 | 0.87 | FPR2 (0.54) | FPR2HCRTR2HCRTR1FYN | |
| SCHEMBL1166141 | 0.86 | FPR2 (0.53) | FPR2HCRTR2HCRTR1TSHRMEN1 | |
| SCHEMBL1167533 | 0.85 | HCRTR2 (0.61) | HCRTR2HCRTR1 | |
| SCHEMBL1166866 | 0.83 | FPR2 (0.60) | FPR2HCRTR2HCRTR1TSHRMEN1 | |
| SCHEMBL2331127 | 0.76 | FPR2 (0.64) | FPR2HCRTR2HCRTR1MEN1KMT2A | |
| SCHEMBL2330742 | 0.75 | FPR2 (0.64) | FPR2HCRTR2HCRTR1SMN1; SMN2 | |
| SCHEMBL2327821 | 0.75 | FPR2 (0.55) | FPR2HCRTR2HCRTR1 | |
| SCHEMBL2324572 | 0.74 | FPR2 (0.68) | FPR2HCRTR2HCRTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110034516-A1 | AMINOPYRAZOLE DERIVATIVES | ACTELION (CH) | 2011-02-10 | — | — | US | claimed |
| US-20110034516-A1 | AMINOPYRAZOLE DERIVATIVES | ACTELION (CH) | 2011-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034516-A1 | AMINOPYRAZOLE DERIVATIVES | CYP3A43, CYP1A2, CYP3A5 | FPR2 1074/4885HCRTR2 2700/4885HCRTR1 2862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.